CX3CR1 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant CX3CR1.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, E |
---|---|
Primary Accession | P49238 |
Other Accession | BC028078 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 2B11 |
Calculated MW | 40396 Da |
Gene ID | 1524 |
---|---|
Other Names | CX3C chemokine receptor 1, C-X3-C CKR-1, CX3CR1, Beta chemokine receptor-like 1, CMK-BRL-1, CMK-BRL1, Fractalkine receptor, G-protein coupled receptor 13, V28, CX3CR1, CMKBRL1, GPR13 |
Target/Specificity | CX3CR1 (AAH28078, 1 a.a. ~ 36 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | CX3CR1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Fractalkine is a transmembrane protein and chemokine involved in the adhesion and migration of leukocytes. The protein encoded by this gene is a receptor for fractalkine. The encoded protein also is a coreceptor for HIV-1, and some variations in this gene lead to increased susceptibility to HIV-1 infection and rapid progression to AIDS. Four transcript variants encoding two different isoforms have been found for this gene.
References
1.The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Johrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP.Cancer Lett. 2009 Jan 8;273(1):127-39. Epub 2008 Sep 7.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.